Relmada Therapeutics (RLMD) Competitors

Anixa Biosciences (NASDAQ:ANIX) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Does the MarketBeat Community favor ANIX or RLMD?

Anixa Biosciences received 17 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 75.56% of users gave Anixa Biosciences an outperform vote while only 35.42% of users gave Relmada Therapeutics an outperform vote.

Company	Underperform	Outperform
Anixa Biosciences	Outperform Votes 34 75.56%	Underperform Votes 11 24.44%
Relmada Therapeutics	Outperform Votes 17 35.42%	Underperform Votes 31 64.58%

Do analysts prefer ANIX or RLMD?

Anixa Biosciences currently has a consensus target price of $9.00, suggesting a potential upside of 170.27%. Relmada Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 566.13%. Given Relmada Therapeutics' higher possible upside, analysts plainly believe Relmada Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Relmada Therapeutics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Is ANIX or RLMD more profitable?

Anixa Biosciences' return on equity of -58.55% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-58.55%	-53.29%
Relmada Therapeutics	N/A	-129.80%	-112.06%

Does the media refer more to ANIX or RLMD?

In the previous week, Anixa Biosciences had 14 more articles in the media than Relmada Therapeutics. MarketBeat recorded 15 mentions for Anixa Biosciences and 1 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.87 beat Anixa Biosciences' score of 0.67 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Anixa Biosciences	Positive
Relmada Therapeutics	Very Positive

Which has higher valuation and earnings, ANIX or RLMD?

Anixa Biosciences has higher revenue and earnings than Relmada Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	510.77	-$12.55M	-$0.38	-8.76
Relmada Therapeutics	N/A	N/A	-$98.79M	-$2.51	-0.30

Which has more volatility & risk, ANIX or RLMD?

Anixa Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.

Do institutionals & insiders have more ownership in ANIX or RLMD?

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 25.3% of Anixa Biosciences shares are held by company insiders. Comparatively, 20.7% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Anixa Biosciences beats Relmada Therapeutics on 12 of the 17 factors compared between the two stocks.